Galenica AG
SIX:GALE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (4.2), the stock would be worth CHf83.89 (0% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.2 | CHf83.65 |
0%
|
| 3-Year Average | 4.2 | CHf83.89 |
+0%
|
| 5-Year Average | 4.1 | CHf81.76 |
-2%
|
| Industry Average | 5.9 | CHf117.76 |
+41%
|
| Country Average | 4.9 | CHf97.53 |
+17%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| CH |
|
Galenica AG
SIX:GALE
|
4.1B CHF | 4.2 | 23 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.3B USD | 7.4 | 23.1 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
60.7B USD | 5.6 | 37.4 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 5.6 | 36.9 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
45.5B USD | 5.7 | 27.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 13.8 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 2.5 | 11.1 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 5.1 | 20.6 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 2.8 | 21.7 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 19.4 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | 0.2 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.5 |
| Median | 4.9 |
| 70th Percentile | 8.3 |
| Max | 378.3 |
Other Multiples
Galenica AG
Glance View
In the picturesque landscape of Switzerland, Galenica AG operates as a stalwart in the healthcare sector, seamlessly bridging the gap between pharmaceutical production and retail distribution. Born from a deep-rooted legacy in delivering health solutions, Galenica combines its prowess in logistics with an extensive network of pharmacies spread across the country. The magic of Galenica's operations lies in its unique dual structure. On one hand, it operates a robust logistics arm, supplying a wide array of medicines to healthcare providers, hospitals, and pharmacies. On the other hand, it runs its own retail pharmacy chains, such as Amavita and Sun Store, alongside an e-commerce platform, which make pharmaceutical care more accessible and customer-friendly for the Swiss populace. Galenica's profitability thrives on this diversified business model. By owning the supply chain from logistics to retail, the company maximizes efficiency and reduces costs, positioning itself as a leader in the Swiss pharmaceutical market. Revenue streams flow from wholesale distribution contracts, retail pharmacy sales, and a growing presence in digital health services. Furthermore, in its operations, Galenica integrates a customer-centric philosophy, leveraging data analytics to optimize stock management and personalize customer experiences—effectively enhancing earnings and customer loyalty. Through meticulous execution and strategic expansion, Galenica ensures that it remains an indispensable player in Switzerland's healthcare framework.